Approach to Acute Liver Failure in Children: A Case-Based Scenario

THE CASE

• Deeply jaundiced, icteric sclerae
• GCS 12/15, disoriented to place and time
• Febrile 38.6°C, HR 118, BP 90/60
• Liver not palpable (shrunken), no splenomegaly
• No asterixis (difficult to assess in children)
• Bilateral Babinski signs

• AST 4,200 U/L, ALT 3,800 U/L
• Total bilirubin 18 mg/dL (direct 14)
• INR 3.8, PT 38 seconds
• Serum ammonia 210 µmol/L
• Creatinine 1.4 mg/dL (elevated for age)
• Blood glucose 52 mg/dL (hypoglycemia)
• pH 7.31, lactate 4.1 mmol/L

STEP 1: RECOGNIZE AND DEFINE PALF

• Severe hepatic dysfunction within 8 weeks of illness onset
• No underlying liver disease
• Liver-based coagulopathy:
  • INR ≥ 1.5 with encephalopathy, OR
  • INR ≥ 2.0 (PT ≥ 20 s) without encephalopathy

This boy meets all criteria: INR 3.8 + encephalopathy (confusion) = PALF confirmed.

STEP 2: IMMEDIATE STABILIZATION (ABC + METABOLIC RESCUE)

Airway & Neurological

• Grade the encephalopathy:
  • Grade 1: Subtle, minimal change in consciousness
  • Grade 2: Disoriented, inappropriate behavior
  • Grade 3: Somnolent but arousable
  • Grade 4: Comatose
  • This boy is Grade 2-3; anticipate rapid progression
• Position: head of bed at 30 degrees
• Intubate early (at Grade 3 encephalopathy) - do NOT wait for Grade 4
• Minimize stimulation; use sedation to reduce ICP

Metabolic Emergencies - Address Immediately

STEP 3: URGENT TRANSFER

"Patients suspected of having ALF should be immediately transferred to a liver transplant center because this can progress very rapidly to fulminant liver failure and then death." - Current Surgical Therapy, 14e

STEP 4: DETERMINE THE ETIOLOGY (Parallel Workup)

Pediatric-Specific Causes to Prioritize:

• Wilson disease - copper accumulation; presents in children >5 years; treatable with D-penicillamine or chelation; liver transplant is curative
• Tyrosinemia type 1 - neonates/infants
• Galactosemia, hereditary fructose intolerance - neonates
• Mitochondrial disorders (POLG mutations) - recurrent PALF; consider in genetic workup
• Reye syndrome - acute encephalopathy + microvesicular steatosis in children/adolescents; associated with salicylates + viral illness

• Viral hepatitis (A, B, E)
• EBV, CMV, HSV, adenovirus (especially in immunocompromised)
• Dengue (consider in endemic regions)

Minimum Workup Panel:

STEP 5: MONITOR FOR AND MANAGE COMPLICATIONS

1. Cerebral Edema and Raised ICP

• ICP monitoring (consider invasive monitoring in Grade 3-4 encephalopathy)
• Head of bed elevated 30°
• Minimize stimulation, sedation/neuromuscular blockade
• Mannitol 0.5-1 g/kg IV bolus for ICP spikes (if serum osmolality < 320 mOsm/L)
• Hypertonic saline to maintain serum Na 145-155 mEq/L (osmotic control)
• Avoid hyperthermia, hypoxia, hypotension - all worsen cerebral edema
• CT head: insensitive early, but rules out intracranial hemorrhage; needed in Grade 3-4 - Current Surgical Therapy, 14e

2. Coagulopathy and Bleeding

• Vitamin K 1 mg/kg IV (up to 10 mg max) to rule out deficiency
• FFP or cryoprecipitate only for active bleeding or invasive procedures
• Avoid routine prophylactic correction (masks INR trend)
• PPI/H2 blocker for GI prophylaxis

3. Hepatorenal Syndrome (HRS) / Acute Kidney Injury

• Avoid nephrotoxic drugs (NSAIDs, aminoglycosides, contrast)
• Careful fluid management; monitor urine output strictly
• Renal replacement therapy (CVVH) if needed

4. Infection and Sepsis

• Common organisms: Gram-positive cocci, Candida species
• Low threshold for blood/urine/BAL cultures and empirical antibiotics
• Fungal prophylaxis in severe cases

5. Hemodynamic Instability

• Splanchnic vasodilation leads to distributive shock
• Norepinephrine preferred vasopressor; terlipressin for HRS

6. Metabolic

• Hypoglycemia: continuous glucose monitoring, D10W infusion
• Hyponatremia: restrict free water; hypertonic saline to maintain Na 145-155
• Metabolic acidosis: treat underlying cause

7. Respiratory

• Risk of pulmonary edema (from fluid overload) and ARDS
• Early intubation at Grade 3 encephalopathy

STEP 6: APPLY PROGNOSTIC CRITERIA - WHEN TO LIST FOR TRANSPLANT?

King's College Criteria (Box 1)

• pH < 7.3, OR
• INR > 6.5 AND serum creatinine > 3.4 mg/dL

• INR > 6.5, OR any 3 of the following:
  • INR > 3.5
  • Bilirubin > 17.6 mg/dL
  • Age < 10 or > 40 years
  • Cause: drug toxicity
  • Time from onset of jaundice to encephalopathy > 7 days

Positive predictive value: 80-100% - Current Surgical Therapy, 14e

Serial Biomarkers for Prognosis

• INR / Factor V level - Factor V has the shortest half-life; most sensitive marker of hepatic regeneration vs. deterioration
• Serum bilirubin trend (rising = poor)
• Serum pH and lactate (persistent acidosis = poor prognosis)
• Arterial ammonia (> 150-200 µmol/L correlates with cerebral herniation risk)
• Serum creatinine (rising = HRS / multi-organ failure)

STEP 7: SPECIFIC THERAPIES (ETIOLOGY-DIRECTED)

STEP 8: TRANSPLANT LISTING AND OUTCOMES

• 1-year patient survival: 73% (vs. 89% for biliary atresia)
• 1-year graft survival: 59% (vs. 78% for biliary atresia)
• Listing rates have decreased (7.7% in 2020) due to improved medical management

• Whole liver transplant (deceased donor)
• Living-donor split liver transplant (smaller pediatric recipients)
• Auxiliary partial orthotopic liver transplant (APOLT) - allows native liver to potentially regenerate; immunosuppression can be weaned if regeneration occurs

CASE OUTCOME

1. Intubated for Grade 3 encephalopathy progressing to Grade 4
2. Transferred to the PICU of a liver transplant center
3. Worked up: Ceruloplasmin low (0.07 g/L), urine copper high, slit-lamp confirmed Kayser-Fleischer rings → Wilson disease diagnosed
4. Started on D-penicillamine + zinc; plasmapheresis initiated as bridge
5. Liver transplant listed; received living-donor transplant from parent on Day 7
6. Post-transplant course complicated by early rejection; treated with pulse steroids
7. Discharged Day 28 on tacrolimus; full recovery, Wilson disease cured

SUMMARY ALGORITHM

Child with jaundice + coagulopathy + altered mental status
               ↓
         CONFIRM PALF
   (INR ≥1.5 + encephalopathy OR INR ≥2.0)
               ↓
   STABILIZE: ABC, glucose, ICP control
               ↓
   TRANSFER to transplant center URGENTLY
               ↓
   PARALLEL: Etiology workup + Monitor complications
               ↓
   Apply King's College Criteria (serial INR, Factor V)
               ↓
   Etiology-directed therapy + Bridge support
               ↓
   TRANSPLANT if criteria met or deteriorating

Recent Evidence (2024-2025)

• Autoimmune hepatitis presenting as PALF (PMID 38700362): Individual patient data meta-analysis (2024) found specific patterns of response to immunosuppression; early steroid trial reasonable but requires expert oversight.
• Recurrent PALF (PMID 41159810): Systematic review (2025) characterized phenotype and long-term outcomes; recurrent PALF often linked to genetic/metabolic causes (especially mitochondrial POLG mutations) and carries high mortality - always pursue genetic workup after first episode.
• Dengue-associated ALF (PMID 39024894): Significant incidence of ALF in dengue infection; relevant in tropical/endemic regions.

What's Inside — All 25 Slides